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Background: Protein kinase C ζ (PKCζ) is a member of the PKC family of
enzymes and is involved in a wide range of physiological processes including
mitogenesis, protein synthesis, cell survival and transcriptional regulation. PKCζ
has received considerable attention recently as a target of phosphoinositide 
3-kinase (PI 3-kinase), although the mechanism of PKCζ activation is, as yet,
unknown. Recent reports have also shown that the phosphoinositide-dependent
protein kinase-1 (PDK-1), which binds with high affinity to the PI 3-kinase lipid
product phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3),
phosphorylates and potently activates two other PI 3-kinase targets, the protein
kinases Akt/PKB and p70S6K. We therefore investigated whether PDK-1 is the
kinase that activates PKCζ.
Results: In vivo, PI 3-kinase is both necessary and sufficient to activate PKCζ.
PDK-1 phosphorylates and activates PKCζ in vivo, and we have shown that this
is due to phosphorylation of threonine 410 in the PKCζ activation loop. In vitro,
PDK-1 phosphorylates and activates PKCζ in a PtdIns-3,4,5-P3-enhanced
manner. PKCζ and PDK-1 are associated in vivo, and membrane targeting of
PKCζ renders it constitutively active in cells. 
Conclusions: Our results have identified PDK-1 as the kinase that
phosphorylates and activates PKCζ in the PI 3-kinase signaling pathway. This
phosphorylation and activation of PKCζ by PDK-1 is enhanced in the presence
of PtdIns-3,4-5-P3. Consistent with the notion that PKCs are enzymes that are
regulated at the plasma membrane, a membrane-targeted PKCζ is constitutively
active in the absence of agonist stimulation. The association between PKCζ
and PDK-1 reveals extensive cross-talk between enzymes in the PI 3-kinase
signaling pathway. 
Background
The protein kinase C (PKC) family comprises serine/thre-
onine protein kinases found in mammalian cells; the 11
distinct isoforms have been implicated in a multitude of
physiological processes [1]. PKC was originally described
as an enzyme that could be activated in vitro and in vivo by
the concerted actions of calcium and diacylglycerol (DAG)
[2,3]. PKCs have been subdivided into three subfamilies
according to their lipid-activation profiles: conventional
PKCs (α, βI, βII and γ) are activated by both DAG and
calcium; novel PKCs (δ, ε, η/L and θ) do not respond to
calcium but require DAG; and atypical PKCs (ζ and ι/λ)
are not activated by either DAG or calcium. The more
recently discovered PKCµ, also known as PKD, may rep-
resent yet another subfamily. All PKCs require the lipid
phosphatidylserine (PS) as a cofactor. 
More recently, phosphorylation of PKC has been revealed
as an important mechanism for regulating its activity 
[4–7]. Studies on PKCβII show that it is regulated by 
phosphorylation at three distinct residues [8–10], at least
two of which are conserved in all other PKC isoforms. One
critical residue for activation is the threonine in the activa-
tion loop (Thr500 in PKCβII, equivalent to Thr410 in
PKCζ) [10–12]. This residue, and the motif surrounding
it, is found in a large number of protein kinases of the
AGC superfamily (protein kinases A, G and C) [13], and in
some cases has been shown to be phosphorylated by an
upstream kinase. Following phosphorylation of the activa-
tion-loop threonine, PKCs rapidly autophosphorylate on a
threonine and a serine residue in the catalytic domain
[10,12]. This leads to full activation of the enzyme and
phosphorylation of substrates. An inhibitory sequence
known as the pseudosubstrate domain is present in the
amino terminus of all PKCs, and is thought to confer auto-
inhibition by binding to the substrate-binding site and
masking one or more phosphorylation site(s) [14]. Upon
lipid binding, a conformational change relieves this auto-
inhibition, allowing phosphorylation to occur. So far, no
direct PKC-activating kinases have been described.
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PKCζ, an atypical family member, has received consider-
able attention recently as it has been implicated as a down-
stream target of phosphoinsitide 3-kinase (PI 3-kinase).
The PI 3-kinase lipid product phosphatidylinositol-3,4,5-
trisphosphate (PtdIns-3,4,5-P3) activates PKCζ in vitro
[15–17]. Stimulation of cells by insulin and insulin-like
growth factor-1 (IGF-1) leads to activation of PKCζ which
can be inhibited by chemical inhibitors of PI 3-kinase
[17–19]. Similarly, activation of PI 3-kinase by lipopolysac-
charide leads to activation of PKCζ which is sensitive to PI
3-kinase inhibitors and a dominant-negative PI 3-kinase
mutation [16]. Activation of PKCζ as a result of expression
of simian virus 40 (SV40) small T-antigen can also be
blocked by inhibition of PI 3-kinase [20]. The closely
related PKCλ isoform is activated in cells stimulated with
epidermal growth factor (EGF) or platelet-derived growth
factor (PDGF) by a PI 3-kinase dependent mechanism
[21]. These findings strongly implicate PKCζ as an effector
of PI 3-kinase in cells. However, the mechanism of regula-
tion of PKCζ by PI 3-kinase remains unknown. Here, we
have examined the mechanism of PKCζ regulation by
phosphorylation and lipids in vitro and in vivo. 
Results
Activation of PKCs following agonist stimulation of cells
has typically been monitored by membrane translocation
or by in vivo 32P-labeling of the enzyme(s). Although con-
ventional PKCs such as PKCα quantitatively translocate
to the membrane following stimulation of cells by phorbol
ester or growth factors, this is not generally true for other
PKCs such as PKCζ. Similarly, these assays do not directly
measure the protein kinase activity of PKCs. Therefore, to
understand the regulation of PKCζ better, we have moni-
tored its activation using immune-complex kinase assays.
Similar assays are routinely used to measure the activation
of the Akt/PKB protein kinase, a PI 3-kinase target that is
also regulated by both lipid binding and phosphorylation. 
PI 3-kinase is both necessary and sufficient to activate
PKCz in vivo
We have used a FLAG-epitope-tagged PKCζ
(FLAG–PKCζ) construct to monitor PKCζ activation fol-
lowing mitogen stimulation. NIH 3T3 cells were tran-
siently transfected with FLAG–PKCζ and its activity was
measured in an anti-FLAG immune-complex protein
kinase assay. PDGF stimulated a two- to threefold
increase in the activity of PKCζ following serum starva-
tion (Figure 1a). This activation was sensitive to the 
PI 3-kinase inhibitor wortmannin at concentrations that
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Figure 1
Activation of PKCζ downstream of PI 3-kinase. (a) NIH 3T3
fibroblasts were transiently transfected with vector alone (pCMV5) or
the FLAG–PKCζ construct, and cells made quiescent in serum-free
medium for 24 h. Cells were pretreated with 100 nM wortmannin
(WM; +), or vehicle (DMSO) alone (–) for 20 min, then stimulated
with PDGF BB (50 ng/ml) for the times (in min) indicated. PKCζ was
immunoprecipitated from cell extracts and the washed
immunoprecipitates assayed for activity. Protein kinase activity was
monitored by phosphorylation of myelin basic protein (MBP), resolved
by SDS–PAGE and quantitated on a Phosphorimager. Total cell
lysates (10% of cell extracts) were resolved on 7.5% SDS–PAGE,
transferred to nitrocellulose, and the levels of PKCζ expressed were
detected by immunoblotting with a PKCζ-specific antibody (α-PKCζ).
(b) 293 cells were co-transfected with vector alone (pCMV5),
FLAG–PKCζ, Myc–p110.CAAX (p110) or GST–∆p85 (∆p85) in the
combinations indicated, and cells serum starved and treated with
wortmannin (WM) as in (a). Cells were stimulated with EGF
(30 ng/ml) for 10 min (+), and cell extracts made. PKCζ was
immunoprecipitated with the FLAG antibody, and an immune-complex
kinase assay using MBP as exogenous substrate was carried out.
Expression of PKCζ was detected with the PKCζ antibody (α-PKCζ),
and Myc–p110.CAAX and GST–∆p85 were detected with Myc-
specific and GST-specific antibodies (data not shown). The results in
(a) and (b) are representative of three independent experiments. 
(c) Sequence alignment of the activation-loop threonine residues of
mouse Akt/PKB (Thr308), human p70S6K (Thr252), rat PKCζ
(Thr410) and rat PKCβII (Thr500). 
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inhibit the accumulation of the PI 3-kinase lipid products
PtdIns-3,4-P2 and PtdIns-3,4,5-P3. Similarly, PKCζ was
activated following EGF stimulation of 293 cells in a
wortmannin-sensitive manner (Figure 1b). In the same
cells, a constitutively active, membrane-targeted mutant
of PI 3-kinase (p110CAAX [22]) stimulated PKCζ activa-
tion in the absence of EGF, also in a wortmannin-sensi-
tive manner. This activated PI 3-kinase mutant has also
been shown to activate Akt/PKB and the kinase p70S6K
in co-transfections [22]. Finally, a dominant-negative PI
3-kinase mutant (∆p85) inhibits EGF-stimulated activa-
tion of PKCζ in these cells. These data provide further
evidence that in two cell types PKCζ is activated down-
stream of PI 3-kinase. Thus, PI 3-kinase, presumably
acting through its lipid products PtdIns-3,4-P2 and
PtdIns-3,4,5-P3, is both necessary and sufficient to 
activate PKCζ.
Recent work on the regulation of Akt/PKB has shown that
a critical event in the activation of this enzyme is the
phosphorylation of the activation-loop threonine (Thr308)
by an upstream kinase (reviewed in [23]). The enzyme
phosphoinositide-dependent protein kinase-1 (PDK-1)
was purified by its ability to phosphorylate Thr308 in
Akt/PKB [24–27]. The equivalent residue in p70S6K is
also phosphorylated by PDK-1, leading to its activation
[28,29]. There is considerable sequence similarity sur-
rounding the activation-loop threonine of Akt/PKB,
p70S6K and PKCζ (Figure 1c). For comparison, the acti-
vation-loop Thr500 residue of PKCβII is shown. There-
fore, we next investigated the possibility that PDK-1
might be the PKCζ upstream kinase. 
PDK-1 stimulates activation and phosphorylation of PKCz
in vivo
NIH 3T3 fibroblasts were co-transfected with
FLAG–PKCζ and a Myc-epitope-tagged PDK-1
(Myc–PDK-1) construct (Figure 2a). The PDK-1 con-
struct used here has previously been shown to activate
Akt/PKB [27]. As shown in Figure 1a, PDGF stimulated
the activation of PKCζ as measured in an immune-
complex kinase assay (Figure 2a). Co-transfection with
PDK-1 caused a constitutive activation of PKCζ in the
absence of mitogen, and this was not enhanced upon
PDGF stimulation. A kinase-inactive variant of PDK-1, in
which the critical Lys110 residue is mutated to an Asn
(PDK-1.K/N), blocked activation of PKCζ by PDGF.
Next, we mutated the activation-loop Thr410 of PKCζ to
an Ala (PKCζ.T410A; Figure 2a). This mutant possessed
lower basal activity than the wild-type enzyme under
serum-starved conditions and could not be activated by
PDGF stimulation. Similarly, PDK-1 did not activate this
mutant in either the presence or absence of PDGF.
These data indicate that PDK-1 is capable of activating
PKCζ in co-transfection experiments, and that this
requires Thr410.
To investigate the phosphorylation of PKCζ induced by
PDK-1, 293 cells were co-transfected with PKCζ or
PKCζ.T410A in the presence or absence of PDK-1, and
cells labeled in vivo with 32P (Figure 2b). In the absence of
PDK-1, PKCζ is heavily phosphorylated, probably reflect-
ing Thr410 phosphorylation and autophosphorylation.
The overall phosphorylation of PKCζ is not increased
upon co-transfection with wild-type PDK-1, but is dramat-
ically reduced in the presence of PDK-1.K/N (Figure 2b).
Little or no phosphate incorporation was observed in the
PKCζ.T410A mutant, and phosphate incorporation was
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Figure 2
PDK-1 activates and phosphorylates PKCζ in vivo. (a) NIH 3T3
fibroblasts were transfected with either vector alone (v; pCMV5), or
co-transfected with the indicated combinations of FLAG–PKCζ,
FLAG–PKCζ.T410A, Myc–PDK-1, and Myc–PDK-1.K/N. Cells were
serum starved for 24 h, then stimulated for 10 min with PDGF. PKCζ
activity was assayed on a FLAG immunoprecipitate using MBP as a
substrate. Equivalent levels of PKCζ and PDK-1 were expressed as
detected by PKCζ (α-PKCζ) and Myc (α-Myc) immunoblotting,
respectively. (b) 293 cells were co-transfected with PKCζ and PDK-1
constructs as in (a) and maintained in 10% fetal bovine serum (FBS)
for 24 h. Cells were then labeled in vivo with 32P. Cell extracts were
made and PKCζ was immunoprecipitated with the FLAG antibody and
resolved by SDS–PAGE, followed by autoradiography. Expression of
PKCζ and PDK-1 was detected by immunoblotting 10% of total lysate
with α-PKCζ and α-Myc antibodies.
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not enhanced upon co-transfection of PDK-1. This
implies that the PDK-1.K/N mutant acts in a dominant-
negative fashion to inhibit activation and phosphorylation
of PKCζ. A kinase-inactive PDK-1 mutant has also been
shown to inhibit insulin-stimulated p70S6K activation
[29]. Eliminating phosphorylation of PKCζ Thr410 may
therefore inhibit subsequent autophosphorylation of
PKCζ. A similar model has been proposed for PKCβII, in
which phosphorylation of Thr500 is a prerequisite for sub-
sequent autophosphorylations [10]. 
PDK-1 stimulates phosphorylation of the PKCz activation
loop Thr410 in vivo
To demonstrate that PDK-1 activates PKCζ by phospho-
rylation of Thr410, and not another residue, we made use
of a phospho-specific antibody raised against the phospho-
rylated activation-loop sequence of PKCβII. Figure 3
shows that this antibody (anti-loop) recognizes PKCβII
from transfected COS cells or rat brain homogenates, but
not PKCβII dephosphorylated by protein phosphatase 1A
(PP1A) in vitro (Figure 3a, top panel). This antibody does
not recognize other phosphorylated residues on PKCβII as
it does not recognize a PKCβII.T500Ε mutant which is
quantitatively phosphorylated at all other phosphorylation
sites (Figure 3a, middle panel). This antibody also specifi-
cally recognizes PKCζ when phosphorylated at Thr410,
but not the PKCζ.T410A mutant (Figure 3a, bottom
panel). In addition, a PKCζ.T410E mutant which is active
as judged by its phosphorylation of myelin basic protein is
also not recognized by this antibody (Figure 3b, bottom
panel). Thus, the anti-loop antibody is specific for the
phosphorylated activation-loop Thr410 of PKCζ. We
therefore used it to show definitively that PDK-1 regu-
lates phosphorylation of this site in PKCζ in vitro and in
vivo. 293 cells were co-transfected with PKCζ or
PKCζ.T410A with either control vector, PDK-1 or PDK-
1.K/N (Figure 3b). In serum-starved cells, the basal activ-
ity of PKCζ correlates with a small amount of
phosphorylation of PKCζ on Thr410, as judged by
immunoblotting with anti-loop antibody. Both the activity
and phosphorylation of Thr410 are increased when PDK-1
is co-transfected. No increase in activity or phosphoryla-
tion was detected when PDK-1.K/N was used.
PKCζ.T410A had little or no detectable protein kinase
activity and was not recognized by the anti-loop antibody,
either in the presence or absence of PDK-1 (Figure 3b).
As events leading to the activation of PKCζ are likely to
occur at the plasma membrane, where both PI 3-kinase
lipid products and PDK-1 are present, we reasoned that
membrane targeting of PKCζ might lead to constitutive
activation of the enzyme, as has been reported for Akt/PKB
[30] and PDK-1 [31]. We fused the amino-terminal myris-
toylation sequence of p60 c-Src to the amino terminus of
PKCζ, and transfected this mutant into cells (Figure 3b).
In serum-starved cells, Myr–PKCζ has a fivefold higher
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Figure 3
PDK-1 phosphorylates PKCζ Thr410 in vivo. (a) Top row, anti-loop
(α-loop) immunoblot of total cell lysates from COS cells transfected
with control vector alone (–) or cDNA encoding PKCβII (+), or the
Triton X-100 soluble fraction of a rat brain homogenate. Cell lysates
were treated with (+) or without (–) protein phosphatase 1A (PP1A,
catalytic subunit) and immunoblotted with anti-loop (α-loop) or anti-
PKCβII (α-PKCβII), as previously described [10]. Middle row, purified
PKCβII or PKCβII.T500E (T500E) treated with or without PP1A and
immunoblotted with anti-loop or anti-PKCβII, as above. The anti-
PKCβII antibody does not discriminate between phosphorylated
forms. Lanes 1,2, 20 ng PKCβII; lanes 3,4, 100 ng T500E; lane 5,
20 ng PKCβII control; lane 6, 20 ng PKCβII autophosphorylated;
lane 7, 100 ng T500E control; lane 8, 100 ng T500E
autophosphorylated. Bottom row, PKCζ, PKCζ.T410A and
PKCζ.T410E expressed in 293 cells and immunoprecipitated with
anti-FLAG antibody. PKCζ activity was determined by an MBP kinase
assay. PKCζ was detected with the PKCζ-specific antibody, and
Thr410 phosphorylation was detected with the anti-loop (α-loop)
antibody. (b) 293 cells were co-transfected with FLAG–PKCζ,
FLAG–PKCζ.T410A or Myr–PKCζ–FLAG and either vector alone (v;
pCMV5), Myc–PDK-1 or Myc–PDK-1.K/N as indicated. Cell extracts
were split into two, and one half was used to assay for PKCζ activity
in an immune-complex kinase assay, as described in Figure 1a. The
other half was immunoprecipitated with FLAG antibody and
immunoblotted with the anti-loop antibody (α-loop). Levels of PKCζ
and PDK-1 expression were detected by immunoblotting with 
α-PKCζ or α-Myc. 
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protein kinase activity compared with wild-type PKCζ,
correlating with an increase in Thr410 phosphorylation.
This could not be further increased by co-transfection of
PDK-1 and, interestingly, could not be inhibited using the
PDK-1.K/N mutant. One possible explanation for this is
that in serum-starved cells, PDK-1 is presumably mostly
cytosolic, whereas Myr–PKCζ is localized at the mem-
brane, and is thus inaccessible to the kinase-inactive PDK-
1.K/N. These data are consistent with the notion that
PKCs are regulated at the plasma membrane. Therefore,
PDK-1 functions as an activating kinase for PKCζ in vivo
by inducing phosphorylation of the activation-loop Thr410. 
Activation and phosphorylation of PKCz by PDK-1 in vitro 
Next, we tested the ability of PDK-1 to directly phospho-
rylate PKCζ in vitro. For these studies, we have used
recombinant fusion proteins of PDK-1, Akt/PKB and
PKCζ. For PDK-1, we generated wild-type and kinase-
inactive (K110I) GST–PDK-1 fusion constructs. These
were expressed in bacteria and purified on
glutathione–Sepharose beads. Akt/PKB was expressed as a
His-tagged fusion protein in baculovirus-infected insect
cells. The recombinant protein was purified on a nickel-
NTA column followed by Mono Q chromatography. The
resulting Akt/PKB fusion protein had an apparent molecu-
lar mass of 70 kDa and was at least 90% pure (not shown).
Finally, PKCζ was expressed as a recombinant wild-type
protein in baculovirus-infected insect cells, and purified to
over 95% purity by conventional chromatography.
To test whether our GST–PDK-1 is functional towards
substrates, we incubated purified GST–PDK-1 with puri-
fied Akt/PKB. In the absence of Akt/PKB, GST–PDK-1
autophosphorylates independently of PtdIns-3,4,5-P3
(Figure 4a). In the absence of PDK-1, Akt/PKB autophos-
phorylates at a low rate. When GST–PDK-1 is added,
however, Akt/PKB is heavily phosphorylated only in the
presence of PtdIns-3,4,5-P3. The inactive GST–PDK-
1.K/I does not phosphorylate Akt/PKB. These data are in
complete agreement with previously reported findings
concerning the phosphorylation of Akt/PKB by PDK-1
[24,25]. Therefore, we proceeded to examine the phos-
phorylation of PKCζ by PDK-1 under similar conditions.
Our purified recombinant PKCζ preparation autophospho-
rylates at a low rate. Incubation of PKCζ with phos-
phatidylethanolamine (PE)/PS mixed vesicles has little
effect on the phosphorylation of PKCζ, either in the pres-
ence or absence of PtdIns-3,4,5-P3 (Figure 4b). When
PDK-1 is added, there is a fivefold increase in the phos-
phorylation of PKCζ with PE/PS, and this can be further
augmented to 12-fold in the presence of PtdIns-3,4,5-P3.
This corresponds to an increase in Thr410 phosphoryla-
tion, as judged by immunoblotting with the anti-loop anti-
body (Figure 4b). GST–PDK-1.K/I does not
phosphorylate PKCζ. Removal of the GST moiety from
GST–PDK-1 by thrombin cleavage had no effect on the
ability of PDK-1 to phosphorylate PKCζ, or the ability of
PtdIns-3,4,5-P3 to enhance this phosphorylation (not
shown). These data are reminiscent of the phosphorylation
of Akt/PKB by PDK-1 in vitro, which also requires PtdIns-
3,4,5-P3. In contrast, p70S6K does not require PtdIns-
3,4,5-P3 for PDK-1-mediated phosphorylation [28]. We
found that PDK-1 phosphorylates PKCζ at a stoichiometry
of 0.46 mol phosphate per mol PKCζ in the presence of
PE/PS/PtdIns-3,4,5-P3. This value agrees well with the
stoichiometry of phosphorylation of Akt/PKB (0.6 mol/mol
[24]) and p70S6K (0.3 mol/mol [28]) by PDK-1. In addi-
tion, we calculated a specific activity of PDK-1 towards
PKCζ (66 units/mg) and Akt/PKB (126 units/mg). These
values are in the same range as those previously reported
for the specific activity of a bacterially expressed
GST–PDK-1 fusion protein [26].
We also tested whether phosphorylation of PKCζ leads to
activation in vitro. For this, we used a PKC substrate
peptide designed on the basis of the optimal substrate
recognition sequence of PKCs [32]. PDK-1 does not signif-
icantly phosphorylate this peptide in an in vitro filter-
binding assay (Figure 4c). Purified PKCζ phosphorylates
the peptide and phosphorylation is not significantly
enhanced in the presence of either PS/PE or
PS/PE/PtdIns-3,4,5-P3 vesicles. PDK-1 caused a two- to
threefold increase in the activity of PKCζ towards the
peptide substrate which could be further enhanced to
sixfold in the presence of PS/PE/PtdIns-3,4,5-P3. The
kinase-inactive PDK-1.K/I did not activate PKCζ in this
assay. These data show that PDK-1 directly phosphorylates
Thr410, and that this is sufficient to activate PKCζ in vitro. 
Association of PKCz with PDK-1 in vivo
As our data show that PKCζ is a PDK-1 substrate, we
explored the possibility that PKCζ and PDK-1 are associ-
ated in cells. NIH 3T3 fibroblasts were co-transfected
with FLAG–PKCζ and Myc–PDK-1 and, following serum
starvation, cells were stimulated with PDGF. Association
between PKCζ and PDK-1 was analyzed by anti-Myc
immunoprecipitation. Figure 5 shows that PKCζ and
PDK-1 can be co-immunoprecipitated in vivo. This associ-
ation was specific to PDK-1 as PKCζ could not be
immunoprecipitated with either non-immune serum or
with irrelevant Myc-tagged proteins (Myc–Rac and
Myc–Pak-1; Figure 5). In addition, this association appears
to be constitutive, as it could be detected in unstimulated
cells and was neither enhanced by PDGF nor inhibited by
the PI 3-kinase inhibitor LY294002. 
Discussion
Our data identify PDK-1 as the first known PKC-activat-
ing kinase. Our results clearly show that PDK-1 induces
PKCζ phosphorylation in vivo, leading to its activation.
Furthermore, PDK-1 directly phosphorylates PKCζ at the
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activation-loop Thr410 residue in vitro. We have also
demonstrated that PKCζ activation can be readily mea-
sured in an immune-complex kinase assay, following stim-
ulation of cells by PDGF or EGF, or co-transfection with
PDK-1. Because these assays are performed in the
absence of PS and PtdIns-3,4-P2/PtdIns-3,4,5-P3, this indi-
cates that once PKCζ is activated, it is covalently locked
into an active conformation. This is reminiscent of the
model proposed for Akt/PKB, in which both PtdIns-3,4,5-
P3 binding and phosphorylation by PDK-1 are required for
activation [23]. However, once fully phosphorylated,
Akt/PKB no longer requires PtdIns-3,4-5-P3 and can be
isolated as an active kinase. Recent studies have shown
that insulin stimulation of rat adipocytes [17] and 32D
cells [18] also leads to activation of PKCζ in a PI 3-kinase-
dependent manner, as measured in immune-complex
kinase assays. Similarly, lipopolysaccharide-treated human
monocytes show increased PKCζ activity which can be
blocked by chemical inhibitors of PI 3-kinase [16].
Whether similar assays can be used to detect activation of
other PKC family members remains to be established.
As PKCζ phosphorylation/activation is almost completely
blocked by co-expression of dominant-negative PDK-1 or
by mutation of Thr410 (Figure 2b), it is likely that a pre-
requisite for PKCζ activation is phosphorylation of
Thr410. Analysis of PKCβII regulation has suggested a
similar mechanism [10]. Phosphorylation of PKCβII
Thr500 is required before the enzyme can autophosphory-
late at two carboxy-terminal sites, Thr641 and Ser660. In
PKCζ, Thr560 (analogous to Thr641 in PKCβII) is con-
served and is therefore likely to be regulated by autophos-
phorylation. However, the second carboxy-terminal site in
PKCζ (analogous to Ser660 in PKCβII) is replaced by a
negatively charged Glu residue (Glu579). This substitu-
tion may confer the same net effect on the protein as
phosphorylation, and may account for the high constitu-
tive activity of PKCζ in certain cell types (Figure 1b),
though this requires further investigation. 
As PDK-1 is recruited to the membrane following agonist
stimulation of cells [31], it is likely that some of its sub-
strates that also have a lipid requirement are also translo-
cated to the membrane. Consistent with this, we find that
a membrane-targeted mutant of PKCζ is constitutively
active in serum-starved cells, and this increase in activity
correlates with an increase in Thr410 phosphorylation.
Similarly, a membrane-targeted Akt/PKB mutant is also
constitutively active in vivo [30]. It is possible that in
unstimulated cells a low level of PtdIns-3,4,5-P3 exists
which may be sufficient to translocate a pool of PDK-1,
but not Akt/PKB or PKCζ. In this scenario, the mem-
brane-targeted Myr–Akt/PKB and Myr–PKCζ would then
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Figure 4
Phosphorylation and activation of Akt/PKB and PKCζ by PDK-1 in
vitro. (a) Purified, recombinant GST–PDK-1, GST–PDK-1.K/I and
His6–Akt/PKB (0.2 µg of each protein) were incubated in an in vitro
kinase assay in the presence or absence of mixed lipid vesicles.
Phosphatidylcholine (PC)/PS mixed vesicles were added at a final
concentration of 100 µM each. Where indicated, 10 µM PtdIns-3,4,5-
P3 (PIP3: synthetic, dipalmitoyl C16 [38]) was added as PC/PS/PIP3
mixed vesicles. The reactions were stopped by addition of SDS
sample buffer and resolved by 10% SDS–PAGE, followed by
autoradiography. (b) Purified PKCζ was incubated in an in vitro kinase
assay with recombinant GST–PDK-1 and GST–PDK-1.K/I (0.2 µg of
each protein), in the presence or absence of PE/PS or PE/PS/PIP3
vesicles, as described in (a). The phosphorylated PKCζ was resolved
by SDS–PAGE, transferred to nitrocellulose and quantitated on a
Phosphorimager. The membrane was then immunoblotted with the
anti-loop antibody (α-loop) to reveal phosphorylation of Thr410. The
data in (a) and (b) are representative of four independent experiments.
(c) Activation of PKCζ in vitro was assayed as described in (b), except
that a PKCζ substrate peptide (RRRRRKGSFRRKK) was added to the
reaction mix. A P81 phosphocellulose paper binding assay was used
to measure incorporation of γ32P into peptide. The data shown are the
means from three independent experiments. 
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be accessible to PDK-1, leading to phosphorylation and
activation. This model is supported by the finding that
PDK-1 has a very high affinity for both PtdIns-3,4-P2 and
PtdIns-3,4,5-P3 [27]. Regardless of the precise mechanism,
the finding that Myr–PKCζ is constitutively active is con-
sistent with the notion that PKCs are enzymes that must
translocate to the plasma membrane for activation. 
Previous studies have suggested that PDK-1 is constitu-
tively active in mammalian cells [26]. Our results,
however, indicate that phosphorylation of PKCζ by PDK-
1 is sensitive to PtdIns-3,4,5-P3, as shown for Akt/PKB. In
the case of Akt/PKB, several studies have indicated that
the PtdIns-3,4,5-P3 requirement is for Akt/PKB itself,
rather than for PDK-1 [24,25]. It has been proposed that
binding of PtdIns-3,4,5-P3 to the pleckstrin homology
(PH) domain of Akt/PKB induces a conformational change
that renders Thr308 accessible to PDK-1. Consistent with
this hypothesis, an Akt/PKB mutant lacking the PH
domain no longer requires PtdIns-3,4,5-P3 for PDK-1-
mediated phosphorylation [25]. In the case of PKCζ, it is
possible that PtdIns-3,4,5-P3 also binds to the regulatory
domain of the enzyme, relieving autoinhibition. Indeed,
although our own results indicate that PtdIns-3,4,5-P3 by
itself is not sufficient to activate PKCζ significantly,
others have presented evidence that both PtdIns-3,4-P2
and PtdIns-3,4,5-P3 alone can stimulate the activation of
PKCζ [15–17] and other PKCs [33–35]. It is likely that dif-
ferent protein preparations and/or assay conditions
account for these disparate results and thus it is difficult to
come to any conclusions concerning the reasons for the
differences. Given that PDK-1 and PKCζ stably associate
in cells (Figure 5), one possibility is that PDK-1 may have
been present in what were presumed to be purified PKCζ
preparations. Although it seems unlikely, we cannot rule
out the fact that the PtdIns-3,4,5-P3 requirement for PDK-
1-mediated PKCζ phosphorylation lies with the PDK-1,
rather than the PKC.
Together, our results identify PKCζ as the third in vivo
substrate of PDK-1, along with Akt/PKB and p70S6K.
There are both similarities and distinctions in the regula-
tion of these three enzymes. First, the PtdIns-3,4,5-P3
dependence of their phosphorylation by PDK-1 differs:
whereas phosphorylation of p70S6K is PtdIns-3,4,5-P3-
independent, that of Akt/PKB is highly PtdIns-3,4,5-P3-
dependent. In contrast, measurable phosphorylation of
PKCζ by PDK-1 is observed in the absence of lipids, and
this is modestly enhanced by PtdIns-3,4,5-P3. Second,
while the co-localization between Akt/PKB and PDK-1 is
PDGF-dependent [31], that between PKCζ and PDK-1
appears to be constitutive and PDGF-independent; asso-
ciation between p70S6K and PDK-1 has yet to be deter-
mined. Third, although both Akt/PKB and PKCζ can be
rendered constitutively active by membrane-targeting,
p70S6K cannot (M.M.C., unpublished observations).
The observation that PKCζ associates with PDK-1 in vivo
suggests considerable cross-talk between effector mole-
cules in the PI 3-kinase signaling pathway. Our data are
consistent with a model in which a pre-existing complex
of PDK-1 and PKCζ exists in unstimulated cells. PDK-1
cannot phosphorylate PKCζ, probably due to autoin-
hibitory mechanisms in PKCζ and/or PDK-1. Following
agonist stimulation, this complex is presumably recruited
to the plasma membrane at the site of PtdIns-3,4,5-P3
synthesis. Here, PDK-1, and possibly PKCζ, bind to
PtdIns-3,4,5-P3 leading to phosphorylation of Thr410 and
activation of PKCζ. It is possible that additional, as-yet-
unidentified events at the plasma membrane may further
contribute to the activation of PKCζ. At this point it is
unclear whether the interaction between PKCζ and PDK-
1 is direct, or whether one or more adaptor/scaffolding
proteins are present. It also remains to be seen whether
other PI 3-kinase effector molecules are also found in
such a complex.
In summary, we have presented evidence that PDK-1 is
the upstream activating kinase for PKCζ. Phosphorylation
of PKCζ Thr410 by PDK-1 leads to activation of the
enzyme, both in vitro and in vivo. Activation of PKCζ must
therefore occur at the site of PtdIns-3,4,5-P3 synthesis,
where PDK-1 is localized. Consistent with this, membrane
targeting of PKCζ renders the enzyme constitutively
active. As the motif surrounding Thr410 is highly con-
served in all other PKC family members, one might
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Figure 5
Association of PKCζ with PDK-1 and Akt/PKB. NIH 3T3 fibroblasts
were co-transfected with the indicated combinations of plasmid DNAs,
then serum starved for 24 h. Cells were pretreated for 20 min with
30 µM LY294002 or with vehicle (DMSO) alone, then stimulated with
PDGF (50 ng/ml) for the times indicated (in min). Anti-Myc
immunoprecipitates (α-Myc) or control non-immune precipitations were
resolved by SDS–PAGE followed by PKCζ (α-PKCζ) immunoblotting.
PDK-1, Rac and Pak-1 were detected by Myc immunoblotting (α-Myc).
Whole cell lysates (WCLs, 10% of that used for the immuno-
precipitation) were also resolved. 
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predict that PDK-1, or a closely related isoform, also phos-
phorylates other PKCs. 
Materials and methods
cDNA constructs
The following cDNA constructs were used in these studies. The FLAG-
tagged PKCζ (FLAG–PKCζ) was generated by addition of the FLAG
epitope (MDYKDDDDK) to the amino terminus of rat PKCζ (GenBank
accession number P09217). The FLAG–PKCζ.T410A mutant was
generated by mutating Thr410 to Ala. Both constructs were subcloned
into the EcoRI sites of the pCMV5 mammalian expression vector [36].
The Myr–PKCζ–FLAG construct was generated by adding in-frame the
first nine amino acids of the p60 c-Src myristoylation sequence
(MGSNKSKPK) to the PKCζ amino terminus and the FLAG epitope to
the carboxyl terminus. The Myc–PDK-1 construct has been previously
described [27]. The kinase-inactive variant Myc–PDK-1.K/N was made
by mutating the conserved critical Lys110 residue to Asn. Generation
of the Myc–p110.CAAX [22] and GST–∆p85 [37] constructs has
been described. The GST–PDK-1 and GST–PDK-1.K/I constructs
were made by subcloning the appropriate PCR fragments of PDK-1
into the BamHI and EcoRI sites of the pGEX 2T vector (Pharmacia).
The PKCβII constructs have been described [11]. All constructs and
mutants were made using PCR and checked by DNA sequencing. 
Cell culture
Early passage NIH 3T3 cells (American Type Culture Collection) and
293 cells were maintained in Dulbecco’s modified Eagle Medium
(DMEM, Life Technologies) containing 10% calf serum at 37°C in a
5% CO2 humidified atmosphere. 293 cells were maintained in DMEM
containing 10% heat-inactivated fetal bovine serum (FBS) at 37°C in a
5% CO2 humidified atmosphere.
Mammalian cell transfections
All transient transfections into NIH 3T3 and 293 cells were carried out
using the Lipofectamine procedure (Life Technologies). Cells were
seeded at a density of 1 × 105 per 35 mm dish 12 h before transfec-
tion. Each DNA construct was titrated against Lipofectamine to achieve
uniform expression of the proteins, typically 1 µg of each DNA, com-
bined with empty vector for a total of 2 µg per dish. The DNA–Lipofect-
amine mix was overlayed onto cells in transfection medium (Optimem,
Life technologies) for 6 h, after which cells were washed and recovered
in complete medium (DMEM + 10% heat-inactivated FBS) for 14 h.
Cells were serum starved in DMEM—serum for 24 hr. For in vivo label-
ing studies, cells were transiently transfected and grown for 24 h in
serum-containing medium then labeled for 2 h with 2 mCi/ml inorganic
32P-orthophosphate (New England Nuclear) in phosphate-free and
serum-free medium before stimulation.
Immunoprecipitations and immune-complex kinase assays
Following stimulation, cells were lysed in 1 ml buffer A (20 mM Tris
pH 7.5, 10% glycerol, 1% NP-40, 10 mM EDTA, 150 mM NaCl, 20 mM
sodium fluoride, 5 mM sodium pyrophosphate, 1 mM sodium vanadate,
1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM phenylmethylsulfonyl fluo-
ride (PMSF)) at 4°C. Ten percent of the total lysate was immediately
boiled in SDS sample buffer. Epitope-tagged proteins were immunopre-
cipitated with 1 µl/ml of the corresponding epitope antibodies, as
follows: FLAG–PKCζ, M2 monoclonal (Kodak—IBI); Myc–PDK-1, 9E10
monoclonal (Boehringer Mannheim) and with 25 µl/ml of a 50% mix of
protein A/G beads (Santa-Cruz). For immune-complex kinase assays,
immunoprecipitates were washed stringently as follows: twice in buffer
B (1× phosphate-buffered saline, 1% NP-40), twice in buffer C (10 mM
Tris (pH 7.5), 0.5 M LiCl) and twice in buffer D (10 mM Tris (pH 7.5),
100 mM NaCl, 1 mM EDTA). Immune-complex protein kinase assays
were carried out in a total volume of 30 µl in the following reaction con-
ditions: 10 mM MgCl2 and 5 µg myelin basic protein (MBP), 10 µCi [γ-
32P]adenosine triphosphate (ATP, New England Nuclear) (25µM) for
10 min at 25°C. Reactions were resolved by 12.5% SDS–PAGE and
MBP phosphorylation quantitated on a Bio-Rad GS505 Molecular
Imager System. For detecting association between PKCζ and PDK-1,
immunoprecipitates were washed twice in buffer B and once in buffer D,
then boiled in SDS sample buffer and resolved by 7.5% SDS–PAGE.
Recombinant protein expression and purification
GST–PDK-1 and GST–PDK-1.K/I were expressed in bacteria as
follows. An overnight saturated culture of bacteria was diluted 10-fold
into 1 liter of medium and cells grown at 37°C with shaking for 1 h. Iso-
propyl-β-D-thiogalactopyranoside (IPTG, 0.5 mM) was then added and
cells grown for a further 16 h at 15°C with constant shaking. Cells
were harvested by centrifugation and pellets rapidly frozen and thawed
at –70°C. Cells were resuspended in buffer E (50 mM Tris pH 8.0,
100 mM NaCl, 1 mM EDTA and 1 mM PMSF), then lysed by addition of
1.5 mg/ml lysozyme (Sigma) and 1.5 mg/ml sodium deoxycholate. Bac-
terial DNA was digested with 10 µg/ml DNase I (Sigma) in the pres-
ence of 1 mM MgSO4 (final concentration). Lysates were cleared by
centrifugation at 15,000 rpm for 30 min at 4°C, and recombinant pro-
teins coupled to 0.5 ml packed glutathione–Sepharose beads (Phar-
macia) at 4°C for 1 h. Beads were washed three times in buffer F
(20 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 1 mM
PMSF), then three times in buffer D. Fusion proteins were eluted with
10 mM glutathione in buffer D, and stored at –20°C in 50% glycerol.
Recombinant Akt/PKB was expressed as a His6 fusion protein in bac-
ulovirus-infected insect cells. Spondoptera frugiperda 9 (Sf9) cells
(500 ml) were grown to a density of 1.5 × 106/ml and infected in a
spinner flask with 50 ml high-titer (5 × 107pfu/ml) baculovirus directing
the expression of a His6–Akt/PKB fusion protein (Bac-to-Bac, Life
Technologies). Infections were carried out for 3 days, after which cells
were harvested by centrifugation and frozen at –70°C. Cells were lysed
in buffer A (in the absence of EDTA) and cleared lysate applied to a
5 ml nickel–NTA column (Qiagen). Following extensive washing with
buffer G (20 mM Tris pH 8.0, 500 mM KCl, 5 mM 2-mercaptoethanol
(ME), 10% glycerol), His6–Akt/PKB was eluted with 100 mM imidazole
in buffer G. Fractions containing the protein peak were pooled, diluted
in buffer H (20 mM Tris pH 8.0, 5 mM ME) and applied to a Mono Q
column on FPLC (Pharmacia). Proteins were eluted with a 40 ml gradi-
ent of NaCl (0–0.5M) in buffer H. Fractions were resolved by
SDS–PAGE and stained with Coomassie blue. The resulting purified
Akt/PKB was stored in 50% glycerol at –20°C. 
Recombinant PKCζ was expressed as a wild-type protein in Sf9 cells
as described above for Akt/PKB. The recombinant protein as purified
over four columns by FPLC, as previously described [33]. The purified
protein was stored in 50% glycerol at –70°C.
In vitro kinase assays
Phosphorylation of Akt/PKB and PKCζ by GST–PDK-1 was assayed in
vitro using 0.2 µg of each protein in a protein kinase assay comprising
20 mM Tris pH 7.5, 10 mM MgCl2, 25 µM [γ32P]ATP (5 µCi per assay,
3000 Ci/mmol). Mixed lipid vesicles were prepared by drying a concen-
trated stock of lipid stored in chloroform:methanol (1:1) under a stream
of nitrogen. Lipids were reconstituted by sonication into 25 mM Tris
(pH 7.5), in an ice bath sonicator (Branson) at 4°C for 10 min at 50%
output. Lipids were prepared fresh for each experiment. Activation of
PKCζ by GST–PDK-1 was assayed as above, except that a synthetic
peptide (RRRRRKGSFRRKK) was added to the reaction mix, at a final
concentration of 100 µM. A P81 phosphocellulose paper binding assay
was used to measure incorporation of γ32P into peptide, as previously
described [32]. Stoichiometry of phosphorylation of Akt/PKB and PKCζ
was determined by a time-course of in vitro phosphorylation of PKCζ
and Akt/PKB by PDK-1 (up to 120 min), separating the proteins by
SDS–PAGE and excising the phosphorylated bands, followed by scin-
tillation counting. One unit of PDK-1 activity is defined as that amount of
enzyme required to transfer 1 nmol of phosphate/min/mg protein.
Supplementary material
Data demonstrating activation of PKCζ by PDK-1 with the GST moiety
cleaved are published with this paper on the internet. 
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S1Supplementary material
Figure S1
The GST tag does not affect the ability of 
PDK-1 to phosphorylate PKCζ. GST–PDK-1
was expressed in bacteria as described in the
Materials and methods section of the paper,
and coupled to glutathione beads.  After
washing in cleavage buffer (10 mM Tris-HCl,
pH 7.5, 100 mM NaCl, 1 mM EDTA, 2.5 mM
CaCl2), 10 µg of protein was treated with
thrombin (0.1 µg, 3800 Units/mg; lane 1, left
panel) or buffer alone (lane 2), and incubated
for 1 h at 4°C. 1 µg of each of PDK-1 and
GST–PDK-1 (eluted from beads with 10 mM
reduced glutathione) were analyzed by
SDS–PAGE (left panel). The cleaved PDK-1
preparation had a molecular mass of
approximately 65 kDa. 0.5 µg of each protein
was used in an in vitro kinase assay with
0.5 µg purified PKCζ as described in the
legend to Figure 4b. The results (right panel)
show that, as presented in Figure 4b, PKCζ
alone has a low intrinsic autokinase activity as
detected by phosphorylation of the PKCζ band
in the presence of [γ-32P]ATP. Phosphorylation
of PKCζ is increased when GST–PDK-1 is
added, and further enhanced when mixed
vesicles containing PE/PS/PIP3 are added to
the reaction mixture. The PDK-1 with the GST
moiety removed is also capable of
phosphorylating PKCζ to the same extent as is
observed with GST–PDK-1. Thus, the GST tag
neither interferes with nor enhances the ability
of PDK-1 to phosphorylate PKCζ, or the ability
of PtdIns-3,4-5-P3 to enhance this reaction.
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